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creativecommons.org/cognitive decline in Alzheimer’s disease. We test whether t-tau and alternative biomarkers of neuro-
degeneration—neurogranin and neurofilament light protein (NFL)—add value in predicting
subclinical cognitive decline.
Methods: One hundred fifty cognitively unimpaired participants received a lumbar puncture for ce-
rebrospinal fluid and at least two neuropsychological examinations (mean age at first
visit 5 59.3 6 6.3 years; 67% female). Linear mixed effects models were used with cognitive com-
posite scores as outcomes. Neurodegeneration interactions terms were the primary predictors of in-
terest: age ! NFL or age! neurogranin or age ! t-tau. Models were compared using likelihood
ratio tests.
Results: Age! NFL accounted for a significant amount of variation in longitudinal change on pre-
clinical Alzheimer’s cognitive composite scores, memory composite scores, and learning scores,
whereas age! neurogranin and age! t-tau did not.
Discussion: These data suggest that NFL may be more sensitive to subclinical cognitive decline
compared to other proposed biomarkers for neurodegeneration.
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2 Cognitive visits, N (% of sample) 150 (100)
3 Cognitive visits, N (% of sample) 141 (94)
4 Cognitive visits, N (% of sample) 101 (67)
5 Cognitive visits, N (% of sample) 17 (11)
Age at baseline cognitive visit, years 59.3 (6.3)
Age at LP, years 61.0 (6.5)
Age difference between LP and cognitive
visits, years
1.7 (2.9)
Female, N (% female) 101 (67)
Parental history of AD, N (% positive) 108 (72)
APOE ε4, N (% positive) 56 (37)
WRAT-3 Reading Subtest Raw Score 51.6 (4.3)
MMSE 29.3 (0.9)
NFL, pg/mL 676 (350)
Neurogranin, pg/mL 388 (176)
Ab42/Ab40 0.09 (0.02)
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Establishing biomarkers that are predictive of cognitive
decline before the onset of dementia is expected to facilitate
early intervention in AD. Recently, the amyloid, tau, and
neurodegeneration [AT(N)] research framework has been
proposed as a biologically based method for classifying in-
dividuals into varying risk categories [1]. In doing so, the
aim is to use biomarker status to predict rate of cognitive
decline and onset of dementia symptoms [2]. However, it
is not yet clear which combination of biomarkers lends the
greatest predictive value.
In the current AT(N) framework, it is proposed that
amyloidosis can be measured with cerebrospinal fluid
(CSF) biomarkers Ab42 or Ab42/Ab40, neurofibrillary tan-
gles with phosphorylated tau (p-tau), and neurodegeneration
with total tau (t-tau) [1]. Yet this framework will continue to
undergo refinements as new biomarkers are discovered and
tested. Indeed, a recently published framework from the
National Institute on Aging–Alzheimer’s Association
(NIA-AA) suggested that other biomarkers of
neurodegeneration—including neurofilament light protein
(NFL) and neurogranin (NG)—should be investigated for
potential added value in predicting cognitive decline [2].
NFL is a key cytoarchitectural protein present primarily
in large-caliber myelinated axons [3]. As such, increased
NFL in CSF suggests degeneration or damage of these
axons. NG, on the other hand, is expressed within dendritic
spines on postsynaptic neurons and plays a key role in plas-
ticity, synapse repair, and long-term potentiation [4].
Increased concentrations of CSF NG signify a loss of
synaptic integrity [5–7].
A small number of studies have compared these bio-
markers across diseases and stages of dementia, as well as
examined their diagnostic accuracy [8–10]. Other research
has investigated their relationships with longitudinal
amyloid accumulation, structural brain changes, cognition,
and brain metabolism in older populations of participants
with varying diagnoses (e.g., cognitively unimpaired, mild
cognitive impairment [MCI], and AD dementia) [8,11].
Yet less is known about the specific role these biomarkers
play in predicting longitudinal, subclinical cognitive
decline in younger populations. This is the major goal of
the present study. Our primary hypothesis is that NFL and
NG will be independently associated with subclinical
cognitive decline and that they will provide additional
predictive value compared to t-tau.P-tau, pg/mL 47 (18)
T-tau, pg/mL 325 (125)
Amyloid positive, N (% of sample) 46 (31)
P-tau positive, N (% of sample) 20 (13)
Amyloid and P-tau positive, N (% of sample) 9 (6)
Values are mean (standard deviation) except where otherwise indicated.
Abbreviations: LP, lumbar puncture; AD, Alzheimer’s disease; APOE ε4,
apolipoprotein E gene ε4; WRAT, Wide Range Achievement Test; MMSE,
Mini–Mental State Examination; NFL, neurofilament light protein; Ab42/
Ab40, amyloid beta 42 and amyloid beta 40 peptide ratio; p-tau, tau phos-
phorylated at threonine 181; t-tau, total tau.2. Methods
2.1. Participants
Demographic characteristics and biomarker levels for all
participants are available in Table 1. One hundred fifty par-
ticipants (67% female) were recruited from the Wisconsin
Registry for Alzheimer’s Prevention (WRAP) [12]. This
observational cohort consists of participants who werecognitively unimpaired at baseline and middle-aged, with
and without parents with AD. All participants are commu-
nity dwelling and underwent examination (including lumbar
puncture for research purposes) at the University of Wiscon-
sin–Madison. Lumbar punctures were performed between
2009 and 2014, and neuropsychological examinations
were performed between 2005 and 2017. Cognitive data
were taken from wave 2 of theWRAP study onward because
of the expansion of the cognitive battery at that time. The
current sample was enriched for AD risk via a parental his-
tory of AD (N 5 108; 72%) and included some participants
positive for at least one allele of the known AD genetic risk
factor apolipoprotein E ε4 (APOE ε4) (N 5 56; 37%). Par-
ticipants with dementia or MCI were excluded from this
study, and no participants who had converted to MCI or de-
mentia over the course of their cognitive visits were
included.
2.2. Standard protocol approvals, registrations, and
patient consents
The University of Wisconsin’s institutional review board
approved all portions of this study, and each participant pro-
vided written informed consent before all procedures.
2.3. Cerebrospinal fluid analyses
Cross-sectional CSF was used in the present study. CSF
biomarker collection, assays, and postprocessing analysis
A.P. Merluzzi et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 129-138 131to account for batch-to-batch variation have been described
previously [13–15]. We measured Ab42, Ab40, and tau
phosphorylated at threonine 181 (p-tau), biomarkers that
distinguish patients with dementia due to AD from
controls [16] and are indicative of conversion from mild
cognitive impairment to dementia [17]. In addition to these
AD biomarkers, we examined markers of neurodegenera-
tion: t-tau, NFL, and NG. These biomarkers have been
associated with cognitive decline in MCI and are elevated
in AD patients compared to controls [8]. To measure global
amyloidosis, we conducted analyses using Ab42/Ab40
(rather than Ab42 alone) given that it is more closely
associated with amyloid plaque burden measured with
molecular brain imaging [18].Table 2
Pearson correlation matrix between biomarkers used in the present study
Biomarker Ab42/Ab40 P-tau T-tau Neurogranin NFL
Ab42/Ab40 1
P-tau 20.14 1
T-tau 20.31 0.80 1
Neurogranin 20.28 0.64 0.74 1
NFL 20.12 0.26 0.32 0.10 1
Abbreviations: NFL, neurofilament light protein; Ab42/Ab40, amyloid
beta 42 and amyloid beta 40 peptide ratio; p-tau, tau phosphorylated at
threonine 181; t-Tau, total tau.2.4. Cognitive composite scores
Longitudinal tests of cognition were used in the present
study. To reduce measurement errors, improve the longitudi-
nal stability of cognitive outcomes, and reduce type 1 errors
associated with multiple comparisons, composite scores
were computed for learning, memory, and executive
function domains, as well as the preclinical Alzheimer’s
cognitive composite (PACC) [19]. Composite scores were
created by computing z-scores from raw scores using the
population means and standard deviations for each constitu-
ent test across all visits (hence, each individual participant’s
number of visits is accounted for). Then, the z-scores within
each cognitive domain were averaged to produce the final
composite. The tests falling into each composite are as
follows:
PACC: Rey Auditory Verbal Learning Test (RAVLT) [20]
total trials 1–5, Wechsler Memory Scale–Revised Logical
Memory delayed recall [21], Wechsler Abbreviated Intelli-
gence Scale–Revised [22], Digit Symbol Coding total items
completed in 90 seconds, and the Mini–Mental State Exam-
ination [23]. This composite differs slightly from the origi-
nally proposed composite [19], which includes the total
recall score from the Free and Cued Selective Reminding
Test [24] rather than the RAVLT.
Learning: RAVLT [20] total trials 1–5,Wechsler Memory
Scale–Revised Logical Memory [21] immediate recall, and
the Brief Visuospatial Memory Test (BVMT-R) immediate
recall [25].
Memory: RAVLT long-delay free recall [20], Wechsler
Memory Scale–Revised Logical Memory delayed recall
[21], and the BVMT-R delayed recall.
Executive functioning: Trail Making Test Part B
(TMT B) [26] total time to completion, Stroop Neuropsy-
chological Screening Test color-word interference total
items completed in 120 seconds [27], and the Wechsler
Abbreviated Intelligence Scale–Revised [22] Digit Symbol
Coding total items completed in 90 seconds. Because higher
raw scores on the TMT B are indicative of poorer perfor-
mance, the z-score for this test was reversed so that higher
composite scores were indicative of better performance.2.5. Statistical analyses
Pearson correlations were performed between bio-
markers for descriptive purposes. For primary analyses,
complete cases were used in linear mixed effects models
within the R lme4 package [28], where the PACC and com-
posite scores for memory, executive function, learning were
used as separate outcomes [15]. In all analyses, a reading
score from each participant wave 2 visit (their baseline visit
for this study) was included as a covariate to control for over-
all educational and intellectual attainment: the Wide Range
Achievement Test 3rd Edition reading subtest [29]. Fixed ef-
fects included sex, APOE ε4 positivity, Wide Range
Achievement Test reading score, age at each cognitive visit
(centered around the mean baseline age of the sample), age
difference in years between the single time point LP and
each cognitive testing session, amyloid positivity (Ab42/
Ab40  0.09) [30], phosphorylated tau positivity (p-
tau  59.50 pg/mL) [30], age ! amyloid positivity, age
! p-tau positivity. In addition to these covariates, each
model included one of the following terms of interest and
its interaction with age: NFL or NG or t-tau. These variables
were standardized before statistical analysis. All models
included random effects of intercept and slope nested within
subject. Nested models with and without the interaction term
of interest were compared using the Akaike information cri-
terion (AIC) and likelihood ratio tests. Statistical signifi-
cance was inferred at a familywise alpha of 0.05, and a
Bonferroni correction was applied for the three primary
models tested within each cognitive composite (final
P5 .017). Variance inflation factors were examined to assess
for model multicollinearity.2.6. Data availability
For purposes of replicating procedures and results,
the data used in this study can be made available upon
request.3. Results
Table 2 shows Pearson correlations between biomarkers.
For descriptive purposes, readers should note the relatively
high correlation between t-tau and p-tau, and the relatively
low correlations between NFL and other biomarkers.
Table 3
Statistical summary of the preclinical Alzheimer’s cognitive composite (PACC), memory composite, and learning compositemodels, including beta coefficients
and standard errors
Predictor variable
Linear mixed effects models
PACC Memory composite Learning composite
T-tau NG NFL T-tau NG NFL T-tau NG NFL
Age (centered) 20.031* 20.031* 20.032* 20.030y 20.029y 20.032* 20.025* 20.024* 20.027*
(0.006) (0.007) (0.006) (0.009) (0.009) (0.009) (0.007) (0.007) (0.007)
Sex 0.158z 0.153z 0.143z 0.356* 0.344* 0.344* 0.188z 0.179z 0.186z
(0.070) (0.070) (0.068) (0.103) (0.103) (0.102) (0.077) (0.076) (0.077)
APOE ε4 20.030 20.032 20.031 20.151 20.146 20.142 20.114 20.104 20.104
(0.070) (0.071) (0.069) (0.103) (0.104) (0.102) (0.078) (0.078) (0.077)
WRAT Score 0.040* 0.039* 0.030* 0.056* 0.054* 0.049* 0.039* 0.037* 0.035*
(0.008) (0.008) (0.008) (0.012) (0.012) (0.012) (0.009) (0.009) (0.009)
Age difference 0.008 0.007 0.003 0.041* 0.041* 0.038* 0.040* 0.040* 0.038*
(0.007) (0.007) (0.007) (0.009) (0.009) (0.009) (0.007) (0.007) (0.007)
Amyloid positivity 20.101 20.075 20.038 20.169 20.101 20.108 20.139 20.079 20.120
(0.082) (0.081) (0.077) (0.120) (0.117) (0.111) (0.093) (0.090) (0.086)
P-tau positivity 20.049 0.0001 0.065 0.041 0.189 0.157 0.078 0.216 0.121
(0.110) (0.110) (0.096) (0.162) (0.161) (0.139) (0.125) (0.123) (0.107)
T-tau 0.044 0.068 0.028
(0.041) (0.060) (0.046)
NG 0.009 20.034 20.068
(0.040) (0.058) (0.044)
NFL 20.012 0.017 0.040
(0.041) (0.059) (0.046)
Age! amyloid positivity 20.008 20.008 0.001 20.012 20.012 20.002 20.006 20.006 0.001
(0.009) (0.009) (0.008) (0.013) (0.013) (0.012) (0.010) (0.010) (0.009)
Age! P-tau positivity 20.018 20.018 20.001 20.052y 20.052y 20.032 20.029 20.031 20.015
(0.014) (0.014) (0.012) (0.020) (0.020) (0.017) (0.016) (0.016) (0.014)
Age! T-tau 0.0001 0.006 0.004
(0.005) (0.007) (0.005)
Age! NG 0.0002 0.006 0.004
(0.005) (0.007) (0.005)
Age! NFL 20.021* 20.016y 20.011z
(0.004) (0.006) (0.005)
Constant 22.080* 22.029* 21.557* 22.944* 22.845* 22.605* 21.989* 21.935* 21.806*
(0.403) (0.403) (0.398) (0.591) (0.591) (0.596) (0.443) (0.439) (0.449)
Observations 559 559 559 559 559 559 559 559 559
AIC 548.5 549.6 511.2 866.8 868.1 860.1 661.8 660.4 656.7
Abbreviations:APOE ε4, apolipoprotein E gene ε4;WRAT,Wide Range Achievement Test; age difference, years between lumbar puncture and cognitive exam-
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composite models are displayed in Table 3 and statistics
for the executive function model are displayed in Table 4.
Plots for the PACC, memory composite, and learning com-
posite are in Figs. 1–3, respectively (while linear mixed
effects analyses were performed across all participants
regardless of biomarker status, Figs. 1–3 display results for
biomarker negative and biomarker positive groups for
illustrative purposes).
PACC: Likelihood ratio tests indicated that age ! NFL
accounted for a significant amount of variation in longitudi-
nal change on PACC scores (c [2](1) 5 26.9, b 5 20.021,
P , .001), whereas age ! NG (c [2] (1) 5 0.001,
b 5 0.0002, P 5 .96) and age ! t-tau (c [2](1) 5 0.0004,
b 5 0.0001, P 5 .99) did not. As seen in Table 3, the fullNFL model (including the age! NFL interaction) had the
lowest AIC of all PACC models.
Memory: Likelihood ratio tests indicated that age!NFL
also accounted for a significant amount of variation in longi-
tudinal change on the memory composite (c [2](1) 5 7.8,
b 5 20.016, P 5 .005), whereas age ! NG (c
[2](1) 5 0.74, b 5 0.006, P 5 .39) and age ! t-tau (c
[2](1) 5 0.59, b 5 0.006, P 5 .44) did not. As seen in
Table 3, the full NFL model (including the age!NFL inter-
action) had the lowest AIC of all memory composite models.
Learning: Likelihood ratio tests indicated that age !
NFL also accounted for a significant amount of variation
in longitudinal change on the learning composite (c
[2](1) 5 5.89, b 5 20.011, P 5 .015), whereas age! NG
(c [2](1) 5 0.67, b 5 0.004, P 5 .42) and age ! t-tau
Table 4
Statistical summary of the executive function composite models, including
beta coefficients and standard errors




Age (centered) 20.068* 20.068* 20.066*
(0.008) (0.008) (0.008)
Sex 0.072 0.077 0.066
(0.096) (0.096) (0.097)
APOE ε4 0.148 0.149 0.144
(0.095) (0.096) (0.095)
WRAT Score 0.037* 0.038* 0.035y
(0.011) (0.011) (0.011)
Age difference 0.029* 0.030* 0.028*
(0.008) (0.008) (0.008)
Amyloid positivity 20.033 20.057 20.046
(0.108) (0.106) (0.102)








Age! amyloid positivity 20.0002 20.001 20.002
(0.009) (0.009) (0.009)








Constant 21.898* 21.941* 21.797y
(0.541) (0.541) (0.552)
Observations 559 559 559
AIC 519.4 520.0 519.2
Abbreviations: APOE ε4, apolipoprotein E gene ε4; WRAT, Wide Range
Achievement Test; age difference, years between lumbar puncture and
cognitive exams; p-tau, tau phosphorylated at threonine 181; t-tau, total
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Table 3, the full NFLmodel (including the age!NFL inter-
action) had the lowest AIC of all learning composite models.
Executive function: No biomarker interaction terms (age
!NFL, age!NG, age! t-tau) were significant for the ex-
ecutive function composite (Table 4). Multicollinearity was
not a significant issue in any model (all variance inflation
factors , 3).4. Discussion
The AT(N) research framework aims to create a
biologically based definition of Alzheimer’s disease and to
classify individuals based on etiology and risk of futurecognitive decline [1]. However, it is not clear which specific
biomarkers will produce the greatest value in predicting
cognitive decline before the onset of dementia. Here, we
demonstrate that—in a cognitively unimpaired, late
middle-aged cohort of individuals at risk for AD—higher
levels of NFL are associated with cognitive decline on the
PACC as well as learning and memory cognitive composites
after accounting for amyloid and p-tau. Further, NFL
exhibits stronger associations with cognitive outcomes
compared to NG or t-tau.
Although the currently proposed AT(N) framework in-
cludes t-tau as a biomarker for neurodegeneration, the util-
ity of this measure in the context of AD remains unclear. It
is typically correlated with p-tau, making it difficult to
draw conclusions about its independent influence or to
build robust statistical models including both these bio-
markers [2,31]; indeed, in this sample, the Pearson
correlation between p-tau and t-tau is 0.80 (see Table 2
for full CSF biomarker correlation matrix). Still, as
mentioned in the Results section, multicollinearity diag-
nostics were normal for all models herein. The fact that
t-tau was not a significant predictor of cognitive decline
in the present study underscores the need for more
research on additional biomarkers for predicting incipient
dementia.
The lack of robust findings for NG was unexpected as
synaptic degeneration is thought to impact the progression
from healthy cognition to dementia and may be predictive
of neuronal loss [6,7,32]. In a cross-sectional study of 132
cognitively unimpaired participants from the WRAP and
Wisconsin ADRC cohorts, NG was associated with poorer
performance on the RAVLT delayed recall test [33]. Yet,
there was no similar relationship found longitudinally for
the composite memory score tested here. One possibility
is that changes in cognitive composites may be more diffi-
cult to detect but are less confounded by measurement er-
rors and are therefore more robust when detected. In
longitudinal studies, NG has been observed to predict con-
version from MCI to frank AD dementia, raising the possi-
bility that increased NG is a robust predictor of cognitive
decline only later in the disease course [34,35]. In partial
support of this hypothesis, NG has also been associated
with longitudinal cognitive decline, but only in amyloid-
positive individuals [8]. Similarly, NG has been shown to
be associated with regional brain atrophy only in
amyloid-positive participants [36]. It is possible that the
relationship between NG and cognitive decline is insuffi-
ciently robust to be measurable early in the disease or
that elevated NG is an important factor only among indi-
viduals who have accumulated measurable AD neuropa-
thology burden.
Yet the literature examining differences in biomarkers
across neurodegenerative diseases suggests other interpreta-
tions for the lack of t-tau and NG findings in the present
study. Although t-tau has been considered a marker of gross
neurodegeneration and axonal atrophy, some observations
Fig. 1. Linear relationships between age (centered on the sample mean), Alzheimer’s biomarker status, and standardized cognitive scores on the preclinical
Alzheimer’s cognitive composite (PACC), adjusted for covariates. The top row represents individuals positive for both amyloid and p-tau pathology, whereas
the bottom row represents individuals negative on these biomarkers. Although linear mixed effects analyses were performed across all participants regardless of
biomarker status, results for biomarker negative and biomarker positive groups are displayed here for illustrative purposes. Blue represents the highest quartile of
t-tau, neurogranin, and NFL, and red the lowest quartile. Higher NFL, but not t-tau or neurogranin, was associated with longitudinal cognitive decline inde-
pendent of amyloid and p-tau concentrations. Abbreviation: NFL, neurofilament light protein.
Fig. 2. Linear relationships between age (centered on the sample mean), Alzheimer’s biomarker status, and standardized scores on the memory composite,
adjusted for covariates. The top row represents individuals positive for both amyloid and p-tau pathology, whereas the bottom row represents individuals nega-
tive on these biomarkers. Although linear mixed effects analyses were performed across all participants regardless of biomarker status, results for biomarker-
negative and biomarker-positive groups are displayed here for illustrative purposes. Blue represents the highest quartile of t-tau, neurogranin, and NFL, and red
the lowest quartile. Higher NFL, but not t-tau or neurogranin, was associated with longitudinal cognitive decline independent of amyloid and p-tau concentra-
tions. Abbreviation: NFL, neurofilament light protein.
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Fig. 3. Linear relationships between age (centered on the sample mean), Alzheimer’s biomarker status, and standardized scores on the learning composite,
adjusted for covariates. The top row represents individuals positive for both amyloid and p-tau pathology, whereas the bottom row represents individuals nega-
tive on these biomarkers. Although linear mixed effects analyses were performed across all participants regardless of biomarker status, results for biomarker-
negative and biomarker-positive groups are displayed here for illustrative purposes. Blue represents the highest quartile of t-tau, neurogranin, and NFL, and red
the lowest quartile. Higher NFL, but not t-tau or neurogranin, was associated with longitudinal cognitive decline independent of amyloid and p-tau concentra-
tions. Abbreviation: NFL, neurofilament light protein.
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tions appear to be relatively specific to AD; t-tau concentra-
tions are typically lower in patients with other
neurodegenerative diseases, such as Parkinson’s disease de-
mentia, Lewy body dementia, and progressive supranuclear
palsy [37–41]. Of course, this is not always the case: tau is
elevated in Creutzfeldt-Jakob disease, adding further
complexity to the role of t-tau in neurodegeneration [42].
With respect to NG, it is important to note that it is not
entirely clear what this biomarker represents. If NG was a
specific marker for synaptic degeneration, one would expect
elevated levels in other neurodegenerative dementias; yet
similar to CSF tau, CSF NG elevation is strikingly AD spe-
cific and may in fact be linked to amyloid-related synaptic
damage [43,44].
An alterative interpretation, therefore, is that these bio-
markers are specific to AD pathophysiology; that is, rather
than reflecting overall neurodegeneration, CSF tau and NG
are excreted from neurons in an AD-specific process,
whereby tau undergoes hyperphosphorylation and neurons
truncate and subsequently secrete t-tau, p-tau, and NG
[45]. Neurofibrillary tangle development, compromised
axonal transport, and degeneration may then occur in these
affected neurons, which would follow the elevated concen-
trations of t-tau, p-tau, and NG detectable in CSF. This inter-
pretation of CSF tau is supported by both animal and human
data: Maia et al. found an Ab-dependent increase in tau
secretion into CSF in APP-transgenic mice in the absenceof neurodegeneration [46]. In addition, stable isotope label-
ing experiments in humans revealed increased tau secretion
into CSF in Ab-positive cases [47]. To the best of our knowl-
edge, similar data for NG do not yet exist.
Interpretations are more straightforward for NFL as a
marker of neurodegeneration. NFL is present in large-
caliber myelinated axons connecting temporal and frontal
lobes [3,48] and is a crucial component of the neuronal
cytoskeleton [49,50]. It is robustly elevated in many
neurodegenerative diseases [48], appears to be relatively in-
dependent of amyloid and tau levels [8,36,51], and correlates
with symptomology, progression, and survival [51,52]. From
a disease mechanism standpoint, this research suggests an
important role for axonal cytoarchitecture in the
development of dementia. NFL may be an especially
promising biomarker for neurodegeneration because it
may be measurable in plasma [53]. Furthermore, because
NFL was associated with cognitive decline while controlling
for Ab42/Ab40 and p-tau in the present study, it may be use-
ful as a predictive biomarker independent of obvious AD
neuropathology. Future studies should test whether the re-
sults observed here can be replicated in blood-based tests
of NFL.
There are several limitations of the present study that
deserve note. First, although CSF Ab42/Ab40 and p-tau are
widely used metrics of AD neuropathology, they do not
capture regional variation in the deposition of amyloid and
tau that may play a crucial role in predicting cognitive
A.P. Merluzzi et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 129-138136decline [54]. Studies using amyloid and tau positron
emission tomography (PET) will be invaluable for deter-
mining whether regional protein accumulation does in fact
add value in predicting cognitive decline before the onset
of dementia. The clinical significance of the cognitive
decline observed in this study remains unclear, although lon-
gitudinal study of this population will lend insight into
whether subclinical cognitive decline on these composite
tests is a robust and acute predictor of MCI or dementia.
In addition, generalizability to other populations may be
difficult: the vast majority of this sample is Caucasian and
highly educated. Intensive recruitment of underrepresented
populations is currently underway.
It is also worth noting the lack of amyloid-related cogni-
tive decline in this study. Other studies have demonstrated
that beta-amyloid deposition is associated with cognitive
decline [55–58], including on individual cognitive tests
[30], and on cognitive composite scores [15]. Many of the
previous studies had larger sample sizes than the present
study and examined relationships between different inde-
pendent variables (CSF vs. PiB-PET) with different depen-
dent variables (individual cognitive tests vs. composite
scores). Clearly, more work will be required to understand
the independent effect of amyloid on cognitive decline,
and whether specific neurodegenerative processes (like
axonal degeneration) mediate this relationship.
Although the results of this study provide data that may
guide selection of markers within the AT(N) framework,
other modalities are also expected to show utility. [18F]
fluorodeoxyglucose positron emission tomography and
structural magnetic resonance imaging are common
methods of indexing neurodegenerative processes [2], and
additional sensitive brain imaging metrics are undergoing
testing and development—including synaptic vesicle glyco-
protein 2A for indexing synaptic density [59]. Ultimately,
research comparing the utility of each of these techniques
will be crucial for creating a valid, biologically based
definition of AD etiology and risk of cognitive decline.
Although continuous variables are useful for describing
biological phenomena from a research perspective, cut
points may ultimately be more useful for bringing
research results into clinical care. Because the AT(N)
framework aims to categorize individuals based on
biomarker status, an important next step in this research
will be to create clinically relevant cut points for neurode-
generation biomarkers, including NFL. To that end, it will
be crucial to follow these participants longitudinally to
determine whether NFL is also predictive of faster decline
to MCI or dementia, rather than the subclinical decline
measured here.5. Conclusion
The data presented here suggest that NFL may lend
additional value to the AT(N) framework and that it may
be more sensitive in detecting cognitive decline before theonset of dementia than either t-tau or NG. Our findings
underscore the idea that axonal degeneration may play an
important role in cognitive decline before the onset of de-
mentia due to AD—or perhaps independent of AD, given
that NFL was associated with cognitive decline indepen-
dently of Ab and p-tau neuropathology. This study also calls
for more research on how t-tau, NG, NFL, and other neuro-
degeneration biomarkers contribute to the pathogenesis of
Alzheimer’s disease.Acknowledgments
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1. Systematic review: The authors reviewed peer-
reviewed literature using traditional methods (e.g.,
PubMed, Google Scholar). There are a number of
papers published on neurodegeneration biomarkers
across disease stages (cognitively unimpaired, mild
cognitive impairment, and dementia) but fewer that
examine longitudinal change in a cognitively unim-
paired cohort.
2. Interpretation: The data presented here suggest that
NFL may lend additional value to the AT(N) frame-
work and that it may be more sensitive in detecting
cognitive decline before the onset of dementia than
either t-tau or neurogranin. Our findings underscore
the idea that axonal degeneration may play an impor-
tant role in cognitive decline before the onset of de-
mentia due to AD—or perhaps independent of AD,
given that NFLwas associated with cognitive decline
independently of Ab and p-tau neuropathology.
3. Future directions: Research is needed to understand
the biological mechanism linking increased NFL
and cognitive decline, as well as research using
more easily attained blood-based biomarkers.References
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